Related Experiment Video
Updated: Jan 5, 2026
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Monalizumab: inhibiting the novel immune checkpoint NKG2A
Thorbald van Hall1, Pascale André2, Amir Horowitz3
1Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, 2333, ZA, Leiden, the Netherlands. T.van_Hall@lumc.nl.
Abstract:
The implementation of immune checkpoint inhibitors to the oncology clinic signified a new era in cancer treatment. After the first indication of melanoma, an increasing list of additional cancer types are now treated with immune system targeting antibodies to PD-1, PD-L1 and CTLA-4, alleviating inhibition signals on T cells. Recently, we published proof-of-concept results on a novel checkpoint inhibitor, NKG2A. This receptor is expressed on cytotoxic lymphocytes, including NK cells and subsets of activated CD8+ T cells. Blocking antibodies to NKG2A unleashed the reactivity of these effector cells resulting in tumor control in multiple mouse models and an early clinical trial. Monalizumab is inhibiting this checkpoint in human beings and future clinical trials will have to reveal its potency in combination with other cancer treatment options.
Insights
A novel immune checkpoint inhibitor, NKG2A, unleashes cytotoxic lymphocytes like NK cells and CD8+ T cells. Blocking NKG2A demonstrated tumor control in preclinical models and early trials, offering new cancer treatment avenues.
Area of Science:
- Immunology
- Oncology
- Cancer Immunotherapy
Background:
- Immune checkpoint inhibitors targeting PD-1, PD-L1, and CTLA-4 have revolutionized cancer treatment.
- NKG2A is a novel checkpoint receptor expressed on cytotoxic lymphocytes, including NK cells and CD8+ T cells.
- Blocking NKG2A can potentially restore anti-tumor immunity.
Purpose of the Study:
- To evaluate the therapeutic potential of blocking the NKG2A immune checkpoint.
- To assess the efficacy of NKG2A inhibition in preclinical cancer models and early clinical studies.
Main Methods:
- Utilized blocking antibodies against NKG2A.
- Tested efficacy in multiple mouse cancer models.
- Conducted an early-phase clinical trial.
Main Results:
- NKG2A blockade enhanced the reactivity of cytotoxic lymphocytes.
- Demonstrated significant tumor control in preclinical models.
- Early clinical data showed promising results.
Conclusions:
- NKG2A is a viable target for cancer immunotherapy.
- NKG2A inhibition, exemplified by Monalizumab, shows potential for cancer treatment.
- Further clinical trials are warranted to explore its combination therapy efficacy.
More Related Videos
08:17Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
Published on: October 30, 2016
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
Related Concept Videos
01:25Immune Surveillance by NK Cells and Phagocytes
Natural Killer Cells: The Fast Responders
NK cells are large granular lymphocytes found in the blood and lymphatic system. These...
01:27Tumor Immunotherapy